A5086940669- Ovarian cancer diagnosis and treatment
- Cancer, Lipids, and Metabolism
- Advanced Breast Cancer Therapies
- Renal cell carcinoma treatment
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Endometrial and Cervical Cancer Treatments
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
Hospital Universitario de Burgos
2021-2024
GEICAM – Spanish Breast Cancer Group
2021
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
<title>Abstract</title> <bold>Background</bold> .Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients platinum-sensitive relapsed ovarian cancer. Nevertheless, there currently limited information regarding this elderly cancer a real-world setting. <bold>Methods.</bold> This observational and multicentric study retrospectively evaluated trabectedin plus PLD setting diagnosed cancer, treated according to Summary Product Characteristics...
Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients platinum-sensitive relapsed ovarian cancer. Nevertheless, there currently limited information regarding this elderly cancer a real-world setting.